For any tools to counter epidemics we need products in the market. This applies to diagnostics as it does to vaccines and drugs. Recent upgrades in regulation make the process of bringing diagnostic products to market more complex. Here is a precedent for how the necessary validation data - incorporating clinical samples from many disease conditions - can be generated more rapidly through collaboration.
thelancet.com/journals/lanin…
x.com/ChariteBerlin/…
thelancet.com/journals/lanin…
x.com/ChariteBerlin/…
Rapid diagnostics are critical during outbreaks, but the EU has tightened regulations for the approval of new tests. Using the #Ebola outbreak, a team led by #CharitéBerlin has found a way to quickly assess the quality of new PCR tests. charite.de/en/research/pa…View quoted post on X